Study Summary
This trialwill test if Time Restricted Eating (TRE) can improve metabolic health and reduce cardiometabolic disease in endometrial cancer patients.
- Endometrial Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
5 Primary · 9 Secondary · Reporting Duration: Baseline (Visit 1), Visit 2 (Week 2), Visit 3 (Week 6 or Week 8), Visit 5 (Week 16)
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Control Schedule
1 of 2
Time Restricted Eating (TRE) Schedule
1 of 2
Active Control
Experimental Treatment
15 Total Participants · 2 Treatment Groups
Primary Treatment: Time Restricted Eating (TRE) Schedule · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · Female Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many individuals are being allocated to this clinical investigation?
"Affirmative, according to clinicaltrials.gov the trial is actively recruiting subjects and was posted on October 7th 2021 before being updated most recently on November 3rd 2022. 15 individuals are required for this study which will take place at a single location." - Anonymous Online Contributor
What aims has this scientific research set out to accomplish?
"The primary goal of this medical study, with measurements taken from the beginning to Week 16, is to identify the proportion of women who agree to participate. Secondary objectives involve tracking alterations in fasting blood glucose (blood sample), electronic blood pressure monitor readings and HDL-cholesterol levels (also through a small sample)." - Anonymous Online Contributor
Is enrollment still open for this research project?
"Affirmative. The information hosted on clinicaltrials.gov specifies that the trial is open for recruitment; it was initially published on October 7th 2021 and its details were last updated November 3rd 2022. There are 15 available spots to be filled in total, all at a single site." - Anonymous Online Contributor